Compare AU
Compare DRUG vs. JPEQ
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the Jpm Us100Q Eq Prem Inc Active ETF (Managed Fund) (JPEQ). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | JPEQ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 2 |
Median incremental investment | $967.00 | $750.00 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,882.65 | $4,944.96 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | JPEQ | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | JPEQ.AX was created on 2023-05-23 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to seek current income while maintaining prospects for capital appreciation. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | JPMorgan Nasdaq Equity Premium Inc ETF (99.66 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (97.22 %) Netherlands (1.57 %) Brazil (0.79 %) |
Management fee | 0.57 % | 0.4 % |
Key Summary
DRUG | JPEQ | |
|---|---|---|
Issuer | BetaShares | JPMorgan |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.4 % |
Price | $8.15 | $64.64 |
Size | $182.401 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 2.54 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 24/05/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | JPEQ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 2 |
Median incremental investment | $967.00 | $750.00 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,882.65 | $4,944.96 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | JPEQ | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | JPEQ |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |